key: cord-0870267-7nixpg97 authors: Bayoumy, Karim; Gaber, Mohammed; Elshafeey, Abdallah; Mhaimeed, Omar; Dineen, Elizabeth H.; Marvel, Francoise A.; Martin, Seth S.; Muse, Evan D.; Turakhia, Mintu P.; Tarakji, Khaldoun G.; Elshazly, Mohamed B. title: Smart wearable devices in cardiovascular care: where we are and how to move forward date: 2021-03-04 journal: Nat Rev Cardiol DOI: 10.1038/s41569-021-00522-7 sha: ae4d9d08db51bb17d3f9b16c216c5bbd7de1850c doc_id: 870267 cord_uid: 7nixpg97 Technological innovations reach deeply into our daily lives and an emerging trend supports the use of commercial smart wearable devices to manage health. In the era of remote, decentralized and increasingly personalized patient care, catalysed by the COVID-19 pandemic, the cardiovascular community must familiarize itself with the wearable technologies on the market and their wide range of clinical applications. In this Review, we highlight the basic engineering principles of common wearable sensors and where they can be error-prone. We also examine the role of these devices in the remote screening and diagnosis of common cardiovascular diseases, such as arrhythmias, and in the management of patients with established cardiovascular conditions, for example, heart failure. To date, challenges such as device accuracy, clinical validity, a lack of standardized regulatory policies and concerns for patient privacy are still hindering the widespread adoption of smart wearable technologies in clinical practice. We present several recommendations to navigate these challenges and propose a simple and practical ‘ABCD’ guide for clinicians, personalized to their specific practice needs, to accelerate the integration of these devices into the clinical workflow for optimal patient care. linear acceleration along three different planes. The other major inertial sensor is the gyroscope, which measures angular motion 7 . The common operation principle of triaxial accelerometers is based on a seismic mass attached to a mechanical suspension system 7 . These devices take advantage of Newton's second law in which mass deflection to the opposite direction of motion with a certain amount of acceleration can be measured electrically. The three most common types of accelerometers are the piezoresistive, piezoelectric and differential capacitive accelerometers, with the differential capacitive accelerometer being the most commonly used in wearables owing to its superior performance 7 . In differential capacitive accelerometers, the seismic mass is suspended between two electrodes and the acceleration of the seismic mass is proportional to the differential capacitance between the electrodes 7 . The advantages of these accelerometers include low power consumption, fast response to motion and superior accuracy compared with the piezoresistive model, which can be undermined by its temperature sensitivity 7 . The placement site on the human body is one of the most important factors that affect the accuracy of accelerometer measurements 7 . A centrally located sensor on the torso (embedded into vests, mounted by straps or attached to the skin) is best suited for detecting posture, acceleration and whole-body movements and offers the least errors compared with other body locations 7 . An ankle-mounted sensor is better suited to measure steps and energy expenditure. However, wrist placement has taken precedence over ankle placement in commercial wearables owing to increased compliance and convenience 8 . Global Positioning System (GPS) and barometers are also included in wearables to more accurately assess physical activity. GPS utilizes a system of 24 or more satellites that are continuously emitting signals to identify their precise orbital position and time based on extremely accurate and stable atomic clocks 9 . With the use of complex equations that include signal emission time and speed of light and account for Einstein's relativistic concepts, the GPS receiver can determine its distance from at least four satellites. The receiver can then trilaterate its position on earth with an accuracy of up to 4.9 m (ref. 9 ). However, GPS function is limited by satellite geometry, signal blockage, building reflections, atmospheric conditions and receiver design features 9 . By contrast, barometers utilize a diaphragm mounted on a vacuum chamber that compresses proportional to pressure. The amount of deformation of the diaphragm is converted to electrical signals via a capacitive model that relies either on plates moving closer together or on a piezoresistive strain model in which resistors on the diaphragm change their electrical resistance according to the extent of deformation 10 . The barometer is then able to determine changes in altitude, track stair count and detect falls on the basis of the principle that atmospheric pressure decreases with increasing altitude 10 . However, barometric measurements can be error-prone because the device might mistake natural changes in ambient temperature and pressure as a change in altitude 10 . Although the use of more sensors leads to better estimation of physical activity and energy expenditure, this approach can also put further strain on battery life 11 . Heart rate and rhythm sensors. Heart rate (HR) measurements during rest and exercise can be used to predict the risk of cardiovascular disease. In healthy populations, a high resting HR has been associated with an increased risk of coronary artery disease and all-cause death 12 and is also well recognized as a predictor of adverse outcomes in patients with heart failure (HF) 13 . An impaired HR recovery after exercise correlates with increased adverse cardiovascular events 14 . HR variability (HRV) has also been strongly linked to the risk of adverse cardiovascular events in healthy individuals and in patients with HF with reduced ejection fraction 15 . Commercial wearables measure HR and heart rhythm through electrocardiography (ECG) or photoplethysmography (PPG) by calculating beat-to-beat time intervals and using algorithms to classify heart rhythm. ECG sensors come in various forms and are the gold standard for HR and heart rhythm measurement. Chest-strap monitors and ECG patches provide continuous monitoring of heart rhythm but are less appealing to the average consumer than other options such as smartwatches given their bulkiness, limited functions and long-term inconvenience. Some smartwatches can record a single-lead ECG as needed by placing a contralateral finger on the crown (negative electrode on the side of the watch), with the back of the watch serving 0123456789();: as the positive electrode 16 . Single-lead ECGs are useful to diagnose simple and common arrhythmias such as atrial fibrillation (AF). However, these single-lead ECGs are often insufficient for the accurate diagnosis of more complex arrhythmias and other conditions such as myocardial infarction (MI) or to detect interval abnormalities unless specific manoeuvres are deployed 17 . PPG measures changes in microvascular blood volume that translate into pulse waves and a tachogram recording 18 . An emitter sends a continuous pulse of photons through the skin and a photodetector measures the variable intensity of reflected photons from the tissue 18 . Most wearables continuously activate the PPG during exercise whereas, during rest and sleep, PPG measurements occur only intermittently to preserve battery life. PPG tachograms, especially when augmented by single-lead ECG, can also identify arrhythmias 19 . Nevertheless, PPG technology has limitations. The main drawback is that the sensor works best when in direct contact with the skin, which is not always the case with wearables secured with straps. Skin colour, moisture and even tattoos have also been postulated to affect PPG accuracy 20 , although one study showed similar device performance across a full range of skin tones 21 . Given the variability in HR accuracy of PPG sensors across different wearable devices, a number of studies have directly compared their performance. One study that investigated the accuracy of the Apple Watch 3 (Apple, USA) and the Fitbit Charge 2 (Fitbit, USA) showed that both devices provided an acceptable PPG sensor HR accuracy (<10% mean absolute percent error) across 24 h and during various activities 22 , including sitting, walking, running and activities of daily living (such as chores or brushing the teeth). Over 24 h, the Apple Watch 3 had a mean difference of -1.80 beats per minute and a mean agreement of 95% compared with the gold standard ECG 22 ; the Fitbit Charge 2 had a mean difference of 3.47 beats per minute and a mean agreement of 91% compared with the gold standard ECG 22 . Another study evaluated the accuracy of several wrist-worn HR monitors (Fitbit Blaze, Apple Watch, Garmin Forerunner 235 (Garmin, USA), TomTom Spark Cardio (TomTom, Netherlands)) and one chest monitor (Polar H7, Polar Electro, Finland) compared with ECG in patients with established heart disease undergoing phase II or phase III cardiac rehabilitation 23 . The chest strap had the best concordance with the standard ECG during all activities (Lin's concordance coefficient r c = 0.99); the accuracy of wrist-worn devices varied substantially by the type of activity and 5% of HR measurements were substantially inaccurate 23 . These studies highlight that PPG HR readings from wrist-worn devices during activity should be interpreted with caution 20 , whereas less convenient, chest-strap monitors are more accurate. Further studies examining newer devices and their performance in diverse populations are needed to further understand the limits of PPG technology and improve its performance. Hypertension is a leading cause of morbidity and mortality globally 24 . Incorporating accurate blood pressure (BP) measurement within consumer-grade wearables has the potential to improve screening for hypertension and identify nocturnal or exercise hypertension, which have been linked to worse outcomes 24 . The HeartGuide wristwatch (Omron, Japan), with a built-in cuff, was compared with an ambulatory BP device in office and ambulatory conditions 25 . For office BP measurements, patients were seated and wearing the HeartGuide wristwatch and the standard BP measurement device in the same nondominant arm and BP readings were taken twice by each device in alternating 30-60-second intervals. For ambulatory BP measurements, patients were given an ambulatory, upper-arm machine that measures BP at 30-minute intervals over 24 h and were instructed to use the HeartGuide device after each ambulatory BP measurement at least 10 times while awake. The mean difference (±s.d.) in systolic BP between both groups was 0.8 ± 12.8 mmHg in the office-based setting and 3.2 ± 17.0 mmHg in the ambulatory setting 25 . These findings are consistent with previously described limitations of wrist-based cuff BP measurements 26 . BP can now be measured without a cuff, increasing the feasibility and ease of monitoring BP throughout the day. This technology uses a combination of PPG and ECG measurements to estimate BP by calculating the pulse transit time, that is, the time required for the arterial pressure wave to travel from the heart to a distant vessel 27 . In a small study, cuff-less BP measurements were compared with ambulatory device measurements 28 . Mean biases between the wearable and ambulatory devices over 24 h were 0.5 mmHg (-10.1 mmHg to 11.1 mmHg) for systolic BP and 2.24 mmHg (-17.6 mmHg to 13.1 mmHg) for diastolic BP, with the mean bias widening over 7 days to -12.7 mmHg for systolic BP and -5.6 mmHg for diastolic BP. Several other variables have been considered to measure cuff-less BP such as pulse wave velocity and propagation in combination with deep learning algorithms; however, most of the studies are limited by small sample sizes and a lack of external validation 29 . Although encouraging, cuff-less BP monitoring is still in its infancy and requires further scrutiny. Other sensors. Biochemical sensors can measure body fluid electrolytes with the use of electrochemical transducers, offering valuable information about plasma volume status and analyte concentrations 30 . However, the accuracy of these sensors changes with skin temperature, skin contamination with dust, dried sweat or other substances, and hair density. One example of biochemical sensors are the minimally invasive continuous glucose monitors that have been clinically validated but are difficult to embed in consumer-grade wearables and mostly function as a stand-alone product 31 . Non-invasive sensors of sweat and saliva might be more practical to integrate into wearables but still need to be carefully evaluated 32 . Biomechanical sensors incorporated into clothing or shoes, such as ballistocardiograms, seismocardiograms and dielectric sensors, have been developed in an attempt to passively and continuously measure variables such as cardiac output, lung fluid volume and weight 1 , which could be beneficial in managing conditions such as HF. Other biomechanical sensors, such as flexible, Nature reviews | Cardiology R e v i e w s 0123456789();: tattoo-like sensors based on microfluidics, are also promising for non-invasive, haemodynamic, continuous monitoring. However, all these emerging sensors still require extensive clinical validation 33 . figure 1 summarizes common smart wearable devices, their embedded sensors and their applications in cardiovascular care. Table 1 lists common wearable products on the market, the published studies on these products and their regulatory status. In this section, we discuss the literature supporting the use of wearable devices in cardiovascular patient care, reviewing the critical clinical studies on the most common cardiovascular applications published in the past 15 years (Table 2) . Global cardiovascular disease risk assessment is traditionally based on clinical risk scores that estimate the 10-year risk. However, most of these scores do not capture the dynamic changes in personalized risk that closely follow lifestyle habits. The incorporation of subjective lifestyle behaviours in risk assessment has been challenging; therefore, objective data derived from wearables provide a renewed opportunity to make the assessment of the risk of cardiovascular disease more accurate, comprehensive and dynamic over a lifetime. Several studies have shown wearable-measured physical activity to have an inverse dose-dependent relationship with all-cause mortality 5, [34] [35] [36] [37] [38] . Moderate-to-vigorous physical activity (MVPA), measured with the use of triaxial accelero meters, was associated with a lower mortality than light physical activity or sedentary behaviour in several US cohorts and in a Swedish population-based cohort [34] [35] [36] [37] [38] . Another study of women with a mean (s.d.) age of 72 (5.7) years showed that as few as 4,400 steps per day were significantly associated with a 41% reduction in mortality compared with 2,700 steps per day, but the benefits levelled at 7,500 steps per day 39 . Of note, stepping intensity was not associated with mortality after adjusting for steps per day. Wearable data also facilitate the application of realtime behavioural change techniques (BCTs) such as just-in-time adaptive interventions, designed to dynamically assess user needs and provide the appropriate amount and type of intervention at the relevant time. Several trials were designed to assess the benefits of wearable-guided BCTs. The mActive trial enrolled 48 outpatients from an academic cardiovascular centre 40 . The prevalence of hypertension, diabetes mellitus and coronary heart disease in study participants was 50%, 23% and 29%, respectively. Trial participants were randomly assigned into two groups, blinded and unblinded to their Fitbug ORB (Fitbug, USA) activity, and evaluated in two phases 40 . The initial phase involved the use of only the tracking device and the second phase entailed the use of smart texts with BCTs for the unblinded group. The smart texts were automated and personalized (coaching SMS messages designed by the physician investigators and informed by real-time activity from the device). The messages were divided into positive reinforcement messages, when participants were on track or had already attained their goal of 10,000 steps per day, or boosting messages to motivate participants who were not on track to reach their goal. The text messaging group increased their daily steps by 2,534 compared with the no-texting unblinded group and by 3,376 steps compared with blinded controls 40 43 . The trial showed that adaptive goals outperformed static goals and small, immediate rewards outperformed larger, delayed rewards, suggesting that adaptive goals with immediate rewards should be preferred to promote physical activity. However, some researchers have questioned the value of activity trackers for health promotion 44, 45 . A four-arm trial from Singapore randomly assigned 800 participants to control (no tracker or incentives), Fitbit Zip, Fitbit Zip plus charity incentives or Fitbit Zip plus cash incentives 44 . The trial showed that a cash incentive was most effective at increasing MVPA at 6 months, but this effect was not sustained 6 months after the removal of incentives. Moreover, despite the improvement in MVPA at 12 months with activity tracking, with or without incentives, these findings did not translate into an improvement in health outcomes, such as weight and BP reduction, at 12 months. The encouragement of physical activity is a cornerstone of primary and secondary prevention; therefore, cardiovascular specialists should familiarize themselves with BCT platforms that have been proven to work and recommend them to their patients, particularly those who have failed to follow traditional counselling for the promotion of physical activity. Frequent wearable-generated HR measurements, such as resting average HR, HR recovery and HRV, can The information is current as of October 2020. BP, blood pressure; ECG, electrocardiogram; HR, heart rate; PA, physical activity; SPO 2 , arterial oxygen saturation. a Search terms used on PubMed.gov included "wearable device name"; all article types included. b Registered at ClinicalTrials.gov; search terms included "device name" in the 'other terms' search tab. c Registered at ClinicalTrials.gov; search terms included "device name" in the 'other terms' search tab and "heart" in the 'conditions' search tab. d FDA clearance means that a class I or II medical device has demonstrated substantial equivalence to another (similar) legally marketed device through a 510(K) premarket submission; FDA approval means that a class III device has demonstrated safety and efficacy after submitting a premarket approval application, the most stringent regulatory category of medical devices. A machine learning algorithm using heart rate and step count was able to classify cardiovascular risk factors such as high cholesterol levels and hypertension Step counting and active minutes [66] [67] [68] [69] [70] TEN-HMS, TIM-HF and BEAT-HF trials showed that a remote telemonitoring intervention did not reduce HF hospitalizations and all-cause mortality [68] [69] [70] The TEMA-HF1 and TIM-HF-2 trial showed that telemonitoring reduced days lost owing to HF hospitalizations and reduced all-cause mortality 66, 67 More studies are needed to assess the value of telemonitoring and remote sensors in HF management; wearables can be used to objectively and frequently assess HF prognosis via 6-minute walk tests or measuring heart rate variables such as heart rate recovery or variability; no clinical studies available Wearables can be used to detect high-risk arrhythmias and stratify patients who might need a defibrillator; no clinical studies available Step counting and heart rate Randomized trials showed that wearableguided exercise prescriptions improve walking ability, speed and oxygen consumption 88, 89 Other trials showed no improvement in walking ability or quality of life but improvement in exercise frequency 90, 91 AF, atrial fibrillation; BP, blood pressure; ECG, electrocardiogram; HF, heart failure; MVPA, moderate-to-vigorous physical activity; PA, physical activity; PPG, photoplethysmography. The global burden of AF and its association with stroke, HF and mortality have been well established 49 . Wearables might be a convenient tool to diagnose asymptomatic or symptomatic AF 20 . The mSToPS study 50 , which included both a randomized trial and a prospective cohort, evaluated the effect of immediate versus delayed continuous ECG monitoring with the use of a Zio patch (iRhythm Technologies, USA) on new AF diagnosis at 4 months and 1 year. The study showed that ECG monitoring led to a higher rate of new AF diagnosis at 4 months and 1 year and was associated with the increased initiation of anticoagulation therapy and outpatient cardiology and primary care visits in patients without previously known AF 50 . The Apple Heart study 19 , the largest remotely conducted study to date, enrolled 419,297 participants in the USA over 8 months to ascertain whether a PPGenabled device could detect AF in individuals without a known history of the disease. Once an initial tachogram met irregularity criteria, the algorithm scanned for PPG irregularities during periods of minimal arm movement. If four subsequent irregular tachograms were confirmed, the participant was notified of an irregular pulse via a notification on the Apple Watch and study app. The positive predictive value for AF detection was 84% and 71% for the irregular notification algorithm and individual tachograms, respectively 19 . In a proof-of-concept study involving the use of Apple Watch-based PPG sensor data, a deep neural network (DNN) algorithm trained with heuristic pretraining showed excellent prediction of AF (C-statistic 0.97) against the gold standard 12-lead ECG 51 . Another study that assessed the use of the Huawei Band 2 (Huawei, China) PRO AF algorithm showed a positive predictive value of 99.6% and a negative predictive value of 96.2% 52 . KardiaBand (AliveCor, USA), now commercially discontinued, coupled with the SmartRhythm 2.0 DNN was compared with implantable cardiac monitors in a study that collected >31,000 h of continuous heart rhythm data and showed a sensitivity of >97% for detecting AF episodes lasting ≥1 h (ref. 53 ). However, the KardiaBand experienced difficulty in interpreting up to 33.3% of recordings in another analysis 53 . The ongoing HEARTLINE trial 54 is the first randomized trial to investigate whether detecting symptomatic and asymptomatic AF with the use of an Apple Watch 4 or a newer model (with combined PPG and ECG) improves clinical outcomes 20 . The trial aims to recruit 150,000 US residents aged ≥65 years and evaluate whether AF detection with a wearable device would improve clinical AF diagnosis, reduce hard outcomes and increase compliance with anticoagulation therapy. The diagnosis of symptomatic arrhythmias has also moved from burdensome strategies, such as the use of bulky Holter monitors, to more convenient wearable monitors. Wearable monitors can provide continuous, single-lead ECG monitoring, such as the Zio patch, or continuous PPG heart rhythm monitoring coupled with as-needed ECG such as the Apple Watch. Although most of these devices are only single lead, they can be as effective or even exceed the ability of conventional Holter monitoring to detect arrhythmias owing to their convenient usability over longer periods of time 55, 56 . A DNN that used single-lead, ambulatory ECG data was able to classify 12 rhythm classes with a high diagnostic performance similar to, and perhaps exceeding, practicing cardiologists 57 . This technology could be applied to wearables in the future. The IPED study 58 was a multicentre, randomized trial that recruited 243 patients who presented to the emergency department with palpitations and presyncope without a clear aetiology. Participants in the IPED study were randomly assigned to an intervention group with KardiaMobile SL (AliveCor, USA) or to standard care. At 90 days, a symptomatic rhythm was detected in 55.6% of participants in the intervention group compared with only 9.5% in the control group. The mean time to symptomatic rhythm detection in the intervention group was 9.5 days compared with 42.9 days in the control group 58 . Although KardiaMobile is not considered a wearable device, wearables with single-lead ECG can be similarly used to diagnose arrhythmias in patients with palpitations or presyncope. Other diagnostic applications. For risk factor screening, a semi-supervised learning algorithm, developed from >57,000 person-weeks of data from Fitbit, Apple Watch and Wear OS (Google, USA), classified high cholesterol levels and hypertension with high accuracy (area under the curve (AUC) 0.7441 and 0.8086, respectively) using HR and step count data available from these commercial wearables 59 . In another study, a convolutional neural network developed with a training dataset of 35,970, 12-lead ECGs and validated in an independent dataset of 52,870 ECGs classified ventricular dysfunction with good accuracy 60 . After a median follow-up of 3.4 years, patients with a false positive (those without ventricular dysfunction by echocardiography but classified by the machine learning ECG algorithm as having left ventricular dysfunction) were at fourfold increased risk of developing ventricular dysfunction in the future compared with patients with a true negative (those without ventricular dysfunction by both echocardiography and the machine learning algorithm) 60 . Of note, these 12-lead ECG prediction algorithms need to be validated with the use of single-lead ECGs before incorporation into wearable devices. Cobos Gil proposed a novel method to use the Apple Watch 4 to obtain standard and precordial leads by manipulating the placement of the watch back crystal and crown on the arms, legs and chest 17 . Although this approach might have limitations, it could be pragmatic as a diagnostic bridge for acute coronary syndromes when a standard ECG cannot be obtained such as in remote rural areas. The current processing power and battery life of wearables might constrain the use of sophisticated machine learning algorithms. Therefore, Sopic et al. created a unique, two-level classification system for MI 61 . This system included an initial screening level, which considered only a few features to detect if any ischaemic abnormalities needed further evaluation, followed by a second-level classifier, which was more computationally demanding but more accurate compared with the screening level. The algorithm was tested on SmartCardia INYU devices (SmartCardia, Switzerland) and achieved a clinically relevant accuracy of 90% for classifying MI 61 . These multi-layered algorithms require extensive validation before being considered for clinical use. Heart failure. In patients with HF, common wearable data, such as physical activity levels, HR, HR recovery and HRV, can be used for risk stratification. For example, one study showed that administering the 6-minute walk test through a pedometer is feasible and can be used to predict HF severity and death 62 . HRV in patients with mildly symptomatic HF can help to identify individuals with limited benefit from cardiac resynchronization therapy 63 . Therefore, the use of wearable-measured HRV might be beneficial in predicting the response to cardiac resynchronization therapy in patients with HF. Emerging biomechanical sensors, such as dielectric sensors, are also promising for HF management but require careful evaluation before clinical adoption. Several randomized trials have assessed the value of remote invasive and non-invasive telemonitoring interventions in HF, with mixed results 64 . One of the landmark trials on remote telemonitoring 65 randomly assigned patients with NYHA class III HF to either a treatment group, in which clinicians had access to pulmonary artery pressure readings from an implanted CardioMEMS Heart Sensor (CardioMEMS, USA), or to a control group, in which clinicians had no access to this information. After a mean follow-up of 15 months, the telemonitoring group had a 39% reduction in HF-related hospitalization compared with the control group 65 . The TIM-HF2 trial 66 randomly assigned 1,571 patients with NYHA class II-III and a left ventricular ejection fraction (LVEF) of ≤45% (or an LVEF of >45% if receiving oral diuretics) to usual care plus remote management or to usual care only. The structured remote intervention consisted of a multicomponent system comprising a three-channel ECG (PhysioMem PM 1000, GETEMED Medizin und Informationstechnik AG, Germany), a BP device, a weight scale and an oxygen saturation device. The intervention, compared with usual care, was associated with a smaller proportion of days lost from unplanned HF-related hospital admissions and had a lower all-cause mortality (HR 0.70, 95% CI 0.50-0.96) after 393 days of follow-up 66 . In the TEMA-HF1 trial 67 , 164 patients with HF and a mean LVEF of 35 ± 15% were randomly assigned to intensive follow-up facilitated by telemonitoring (daily BP, weight and HR measurements with the use of electronic devices) or usual care. The intervention group had a significantly lower all-cause mortality (absolute reduction of 12.5%) and a lower number of follow-up days lost to death, hospitalization or dialysis. However, this effect might have been due to the thorough follow-up and not necessarily to the use of remote devices 67 . Although certainly promising, other trials have not shown the same favourable outcomes. The TEN-HMS home telemonitoring trial 68 used wearable and non-wearable non-invasive monitors (home BP monitor, weigh scale and single-lead ECG on a wrist band) in patients with an LVEF of <40% and a recent hospital admission for HF and showed no significant differences in days lost owing to hospitalization or death compared with nurse telephone support or usual care at 240 days, although the telemonitoring group had a lower mean duration of hospital admission by 6 days. The TIM-HF trial 69 randomly assigned 710 patients with an LVEF of ≤35%, NYHA class II-III and a history of HF decompensation within the previous 2 years to telemonitoring (weight, BP and heart rhythm data transmission) compared with usual care and found no differences between the groups in cardiovascular and all-cause mortality or in hospitalizations at a median follow-up of 26 months. One of the largest trials on telemonitoring in HF, the BEAT-HF study 70 , randomly assigned 1,457 elderly patients hospitalized for HF (median LVEF of 43%) to usual care or to remote care after hospital discharge consisting of telemonitoring (daily collection of BP, HR, symptoms and weight data) combined with telephone-based coaching. The trial had low adherence rates in the remote-care group; only 61.4% and 55.4% of patients assigned to this group were >50% adherent to telephone calls and telemonitoring, respectively, within the first 30 days. Moreover, the remote care intervention did not lower the rate of hospital readmission for any cause at 30 days or 180 days after hospital discharge 70 . Other smaller studies have shown mixed results 52, 64 . Trials on HF telemonitoring have considerable differences in inclusion criteria and trial design such as the types of remote devices used and variables collected, thereby limiting the reproducibility and generalizability of these studies. In addition, most trials had a risk of bias due to the lack of blinding. Larger trials with more standardized protocols that utilize validated devices and ensure higher adherence rates might shed further light on the true value of wearable sensors in HF management. We have discussed the use of wearables to diagnose symptomatic or asymptomatic AF in previous sections; in this section, we now focus on the applications of wearables in individuals with established AF. Non-invasive, continuous heart rhythm data generated by wearables have the potential to shift the definition of AF from a categorical to a continuous and quantifiable entity, opening new frontiers in anticoagulation and rhythm control strategies. Wearables can further empower patients with AF in their care through a targeted approach to anticoagulation coinciding with the episodes of AF 71 . A study of patients with AF who underwent catheter ablation showed that twice-daily pulse checking and the initiation of direct oral anticoagulants when a pulse irregularity was detected was a feasible practice 72 . The REACT.COM pilot study 73 recruited patients with an implantable cardiac monitor to initiate anticoagulation if the patient developed an AF episode of ≥1 h. This study showed a 94% reduction in anticoagulation use compared with chronic anticoagulation treatment 73 , with a saving of approximately US$800 per patient over 3 years 74 . Similarly, the iCARE-AF study 71 randomly www.nature.com/nrcardio assigned patients with paroxysmal AF to continuous or as needed anticoagulation according to KardiaMobilegenerated ECG recordings. The study demonstrated the feasibility of this approach but patient compliance was a concern compared with an implanted monitor 71 . Utilizing wearables to tailor anticoagulation regimens holds great potential but should be judiciously used in select patients according to their individual compliance and risk of stroke. Turakhia et al. are currently developing a large (n = 5,000) trial of rhythm-guided treatment with direct oral anticoagulants with the use of smartwatches (M.P.T., unpublished work). The trial will be powered for superiority for major bleeding events and non-inferiority for ischaemic stroke. Wearables might also be used to confirm persistent AF in patients before presenting for elective cardioversion, thereby preventing unnecessary hospital visits and costs 53 . Finally, this technology might have value in optimizing the ventricular rates at rest and during exercise in patients with permanent AF 75 . Strategies for the secondary prevention of coronary artery disease aim to prevent recurrent events by improving the control of modifiable risk factors. The MiCORE study 76 enrolled 200 patients with type I MI across four US hospitals who received a guideline-driven, self-management programme comprising a mobile application integrated with an Apple Watch and a Bluetooth BP cuff. Preliminary results from 164 patients showed a 43% lower likelihood of hospital readmission at 30 days among participants receiving a guideline-driven, self-management programme than among participants in a propensity-matched, historical comparison group (n = 695) 76 . Furthermore, a cost-effectiveness analysis concluded that as much as US$6,000 per patient were saved by implementing this intervention 77 . Randomized trials examining the benefits of these platforms have the potential to revolutionize care in patients with MI. Although not yet studied, wearables can also potentially be used to titrate β-blocker dosage in patients with chronic coronary syndrome and to screen for atrial or ventricular arrhythmias after MI, especially in patients with a reduced ejection fraction. can predispose patients to life-threatening arrhythmias. However, monitoring this abnormality is difficult and requires a 12-lead ECG. The single-lead ECG patch BodyGuardian (Preventice Solutions Group, USA) was compared with 24-h, 12-lead Holter monitoring in 25 patients with congenital long QT and in 20 healthy individuals and the mean of the Bland-Altman plot was almost 0 with a small standard error (−1.4 ± 1.8 ms) 78 . Another study applied a convolutional DNN, trained from >560,000 manually annotated QTc intervals on 12-lead ECGs, to analyse prospectively collected, manually annotated lead I and II data from a standard 12-lead ECG and from the KardiaMobile 6-lead ECG in 145 patients with prolonged QTc 79 . The mean difference in the algorithm-predicted QTc from the KardiaMobile 6-lead ECG versus the annotated 12-lead ECG was 4.90 ms but with a large s.d. of 21.58 ms. The use of single-lead ECGs embedded in most wearables might not be practical for accurate QTc measurement, but accurate QTc measurement might be possible with innovative approaches such as device manipulation to record multi-lead recordings 17 and advances in artificial intelligence (AI) algorithms. Hyperkalaemia. Hyperkalaemia is a common cause of life-threatening arrhythmias in patients with cardiovascular disease, especially in individuals with underlying renal insufficiency 80 . ECG monitoring has been touted as a method to recognize the arrhythmogenic effects of severe hyperkalaemia such as peaked T waves, QRS widening, PR shortening and bradycardia. However, evidence is conflicting as to whether these findings are reliable, especially in patients with chronic hyperkalaemia 81 . A study evaluated the performance of an established DNN 82 for the detection of hyperkalaemia in 10 patients undergoing haemodialysis who also underwent 4 h of ECG recording with the use of an investigational AliveCor device and concurrent blood testing 83 . A total of 5.4 h of data in a hyperkalaemic state and of 44.1 h otherwise was recorded. The sensitivity by duration of hyperkalaemia was 94% and the specificity was 74%, suggesting that this AI algorithm is a viable and non-invasive option for the screening of hyperkalaemia at home 83 . However, caveats such as high false-positive and false-negative rates and the need for continuous ECG monitoring curb the current enthusiasm supporting the use of available off-the-shelf wearables to diagnose hyperkalaemia. However, novel advances in sensors and software algorithms over the next few years might improve our ability to detect hyperkalaemia or other electrolyte abnormalities via ECG or, even better, with biochemical sensors. Cardiac rehabilitation is a mainstay in the management of many cardiovascular conditions because it provides a structured exercise programme together with comprehensive guideline-directed secondary prevention. Telerehabilitation programmes supported by real-time wearable data might revolutionize home-based rehabilitation and relieve the inconvenience and cost associated with centre-based programmes that currently lead to low participation rates. A meta-analysis of 23 randomized trials, including a total of 2,890 patients undergoing cardiac rehabilitation after MI, revascularization or HF diagnosis, showed that a home-based form of cardiac rehabilitation was as effective as centre-based rehabilitation in improving clinical and health-related quality-of-life outcomes 84 . However, most of these studies did not use wearable devices. A non-inferiority, randomized trial comparing REMOTE-CR -a real-time, remote telerehabilitation platform that includes the use of a chest-worn wearable sensor (BioHarness 3, Zephyr Technology, USA) -with a centre-based programme showed that REMOTE-CR was associated with less sedentary time at 24 weeks and was more cost-effective than the centre-based programme 85 . The REMOTE-CR platform leveraged social cognitive theory to improve self-efficacy and self-determination (essentially, the belief that they can exercise more) in patients in the REMOTE-CR group 85 . Furthermore, a systematic review and meta-analysis of nine trials of patients with cardiovascular disease demonstrated that wearable monitors of physical activity that included exercise prescription or advice were superior to no device in improving fitness and step count in the maintenance phase of cardiac rehabilitation 86 . Although virtual home-based telerehabilitation is already available, additional highquality and generalizable randomized clinical trials could usher in a future that will greatly expand access to this evidence-based intervention. In patients with peripheral vascular disease, the first-line treatment for intermittent claudication is a supervised exercise programme of gradually increasing intensity. A pilot study randomly assigned 37 patients with peripheral vascular disease to use a feedback-enabled Nike FuelBand (Nike, USA; now commercially discontinued) and a supervised exercise programme (intervention group) or to a supervised exercise programme without the band (control group) 87 . Instead of exercise prescriptions guided by the number of steps, 'fuel points' were used to estimate overall activity. These fuel points were reviewed at follow-up visits and customized exercise prescriptions were programmed into the devices of patients in the inter vention group. The study showed significant increases in maximum walking distance, claudication distance and quality of life, sustained over 12 months, in the intervention group compared with the control group 87 . Two randomized trials of >100 patients with peripheral vascular disease, each utilizing the ankle-based accelerometer StepWatch 3 (Modus, USA), showed that wearableguided exercise prescriptions were associated with a significant improvement in walking ability, speed and peak oxygen consumption 88, 89 . Conversely, a wearable activity monitor combined with telephone coaching did not improve walking ability or quality of life but improved exercise frequency in a trial of 200 patients with peripheral vascular disease 90 . Other studies have shown variable results 91 . Although we need to continue to study the role of wearables in peripheral vascular disease, we must consider the use of the devices and exercise protocols that have proven benefits in this patient population. Understanding the triggers and barriers of wearable devices requires close collaboration between medicine and technology as well as knowledge of how the technology will be adopted and accepted through different stakeholders, from clinicians to regulatory bodies to users. Today, several challenges are still hindering the widespread adoption of wearable devices in clinical practice, the most important of which we discuss in this section (Table 3) . Creative evaluation frameworks, pragmatic regulatory policies and simple clinician guides are needed to accelerate the integration of these devices in routine practice and propel us toward a new decade of health democratization. Hardware and software accuracy and validity. Consumers, fuelled by the hype of trendy but often unproven technologies, are pushing for the rapid adoption of wearables in clinical practice but we, as a scientific community, must tread with caution. Inaccurate data is more harmful than no data. Many validation studies have questioned the accuracy of raw sensor data and software algorithms [92] [93] [94] . The heterogeneity in wearable data quality can be attributed to the lack of consensus on the development and design of digital health products and the obscurity of regulatory oversight policies. At the beginning of 2020, Coravos et al. developed a timely evaluation framework to test the accuracy and validity of connected sensor technologies, which included wearables 95 . In this comprehensive framework covering both the hardware and software components of these technologies, the authors outline the potential resources, evaluation criteria and target thresholds for five dimensions: verification, analytical validation and clinical validation (V3); data security and privacy; data rights and governance; utility and usability; and economic feasibility 95 . Meticulous scrutiny of these devices through such structured frameworks ensures that they are worthy of clinician and patient trust by the time they reach the market. The absence of clear regulatory oversight policies governing commercial wearable devices has also led to the emergence on the market of numerous products of unknown safety and efficacy. Medical-grade sensors such as wearables with ECG are usually regulated by regulatory agencies such as the FDA risk-based medical device policy in the USA, which is the most rigorous agency and often labels these sensors as class I or II medical devices. The FDA often clears these sensors through the accelerated 510(k) pathway if the applicant can show substantial equivalence to a US legally marketed predicate device 96 . Rarely do these devices receive approval for a new indication label, which requires randomized trials showing clinical efficacy (Table 1 ). Owing to these policies, the performance of medical-grade sensors tends to be more consistent across various wearable manufacturers compared with non-medical sensors, such as activity or PPG sensors, which do not undergo FDA evaluation. Clinicians and patients must exercise caution when interpreting data from unregulated sensors. For example, abnormal PPG HR measurements are often error-prone and should be interpreted in the context of device placement, user activities and symptoms. Software algorithms that deploy AI to analyse sensorcollected data continue to evolve in breadth and complexity, allowing the efficient processing of large amounts of data that greatly exceed human cognitive capacity. Augmented AI is expected to complement traditional data analytics and clinical care to improve patient outcomes and lower costs. However, the performance of AI algorithms in medical tasks still faces considerable technical and ethical challenges such as the ability to detect confounding variables in inadequately labelled datasets, the difficulty of integration in clinical workflows, bias and non-representative population data, risk of aggravating health disparities, interpretability of 'black box' unsupervised algorithms, and uncertain regulatory and tort environments 97 . In addition, the lack of transparency and reproducibility of AI computational algorithm methods and code in many published www.nature.com/nrcardio studies threatens scientific progress and discovery, which require that independent scientists are able to scrutinize and reproduce results 98 . The US National Academy of Medicine issued a reference document for the responsible development and maintenance of AI in the clinical setting that provides a guiding framework for all stakeholders, including AI developers and the medical community 99 . Furthermore, regulatory agencies such as the FDA have realized that the fast iterative and dynamic development of medical software technologies is vastly different from hardware. The FDA new digital health innovation plan promises a pragmatic risk-based approach to regulate software as a medical device through a pre-certification programme that aims to look first at the software developer rather than at the product 100 . The FDA then leverages the International Medical Device Regulators Forum risk categorization framework to help the pre-certified company determine the appropriate premarket pathway for its product. Finally, post-marketing surveillance of real-world data is used to verify the software's efficacy and safety. As this novel strategy enters its pilot phase, the FDA should continue to solicit feedback from all stakeholders, including clinicians, scientists, technologists and industry leaders, and learn from the proposed comprehensive software and hardware evaluation frameworks such as that by Coravos et al., which could improve this programme 95 . Other global regulatory agencies can closely monitor the implementation of the FDA plan and improve on it to facilitate the rapid introduction of high-quality and low-risk devices into clinical care. Defining meaningful use criteria for wearables requires building an extensive body of evidence that unequivocally proves benefit and rules out harm. This approach requires that we separate noise, which might be anxietyprovoking for both patients and clinicians, from actionable and meaningful clinical information. For example, does long-term, continuous ECG monitoring in asymptomatic young individuals provide any meaningful clinical information? In Table 1 , we summarize the number of completed or ongoing studies listed on PubMed.gov and ClinicalTrials.gov examining the clinical applications of wearables. Small, proof-of-concept studies are abundant but the larger, well-designed randomized trials, such as those examining wearables in peripheral vascular disease or AF, set a worthy example for others to follow. The technology industry should learn from the veteran pharmaceutical industry that a continued investment in evidence generation, particularly randomized clinical trials, increases patient and clinician trust and maximizes Nature reviews | Cardiology the return on investment if a new label indication, not only clearance, is granted by a regulatory agency. Given that wearable software and hardware components are validated through evaluation frameworks and regulatory pathways, the duty of our medical community and US federal agencies, such as the Centers for Medicare and Medicaid Services, will be to agree on the best practice clinical guidelines and meaningful use criteria for these devices. For example, the Apple Heart Study sparked a debate on how a small false-positive rate can increase downstream medical testing and costs if screening is applied to the entire general population. Alternatively, false negatives can have detrimental consequences, especially in symptomatic or high-risk patients in whom false reassurance can delay anticoagulation therapy and increase the risk of stroke 101 . Therefore, cardiology society guidelines have not yet endorsed the use of the Apple Watch for AF screening. However, the ongoing HEARTLINE trial 54 aims to further evaluate whether the newer Apple Watch models, augmented by a single-lead ECG sensor, can improve screening accuracy and clinical outcomes, which could potentially change guideline recommendations. Finally, as several colleges and postgraduate training programmes across different health-care disciplines are in the process of developing telehealth curricula to cope with the COVID-19 pandemic 102 , these curricula should incorporate structured learning modules about common wearables, their current clinical applications and the potential to improve remote patient care. Despite the promise of wearable-guided BCTs, their ability to maintain long-term behavioural change remains a concern. As mentioned previously, a trial with 800 participants questioned the value of wearables in sustaining long-term behavioural changes and improving clinical outcomes 44 . In another small study, 67 participants with overweight or obesity received a Fitbit One to wear and 50% of the participants were randomly assigned to receive text message prompts 45 . The group receiving the text message intervention showed an increase in the number of steps. However, this effect was not sustained over the 6-week study period. Heterogeneity in the design and implementation of BCTs has been a considerable challenge and efforts have been made to standardize the methods to create these tools 103 . Hekler et al. proposed a framework for the use of digital BCTs, such as just-in-time adaptive interventions, to encourage and maintain health 104 . The merit of this framework is that it recognizes the personalized health needs of the participants. This framework highlights the importance of the 'state-space' , essentially the readiness to respond to an intervention according to intrinsic factors (state) and contextual factors (space). For a real-world example, the framework of a behavioural intervention might use GPS and time of day to identify when a person is at work versus at home to deliver the correct amount of encouragement to engage in physical activity. However, digital models often require programming for a strict definition of the desired outcome and the type and amount of intervention proposed and are in constant flux to tailor interventions 104 . Zhou et al. produced a tool to pre-empt the problem of non-adherence with use of a Discontinuation Prediction Score 105 . The researchers utilized data from the mPED study, which enrolled women who were physically inactive, and randomly assigned participants to physical activity interventions (counselling or app-based), creating a score that would predict the risk of relapse in the following week with the use of accelerometer data. The score had an AUC of 0.9 with high accuracy (>80%) and specificity (>80%). A simulation was then performed in which financial incentives were allocated based on an individual's predicted exercise adherence, resulting in a theoretically greater adherence compared with a random incentivization scheme. Therefore, the use of behavioural economics and cognitive psychology to develop novel social and financial incentives can potentially sustain good habits, especially when initiated at a very young age 44 . For example, some wearable companies have launched a connected lifestyle coaching platform for insurance plans, employers and health-care systems that leverages inherent reward programmes and financial incentives to promote healthy behaviours in individuals and families 106 . Although two-thirds of millennials in one survey agreed to share their wearable data with insurance companies 1 , applying financial and non-financial rewards with penalties raises several ethical questions. Can consumers simply opt out of these programmes without consequences if they choose not to share their data? How are these programmes managed for individuals who cannot afford a wearable device or for those with low digital literacy? Are there clear data user agreements that govern data sharing with third parties? Future post hoc analyses of these programmes will shed light on their value in enacting long-term behavioural changes, particularly in challenging populations such as in elderly people and individuals with low digital literacy. Hardware cost and payment models. The cost of wearables varies substantially and the cost-utility ratio is subject to the full range of health and non-health features unique to each device. A survey among 4,272 US adults reported a threefold difference in wearable use between individuals earning ≥US$75,000 and those earning